Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer

[1]  K. Tanaka,et al.  Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells , 2004, British Journal of Cancer.

[2]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[3]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[4]  A. Harris,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Morris.  The Role of EGFR-Directed Therapy in the Treatment of Breast Cancer , 2002, Breast Cancer Research and Treatment.

[6]  C. Arteaga.  Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. , 2002, Seminars in oncology.

[7]  Roy S Herbst,et al.  Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Arteaga.  Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.

[9]  M. Kris,et al.  ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[11]  H. Kurokawa,et al.  Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[13]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[14]  B. Katzenellenbogen,et al.  A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. , 2000, Endocrinology.

[15]  Simak Ali,et al.  Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.

[16]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[17]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[18]  J. Foekens,et al.  Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.

[19]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[20]  F. Taggi.  SAFETY HELMET LAW IN ITALY , 1988, The Lancet.

[21]  L. Jackson.  Chromosomes and cancer: current aspects. , 1978, Seminars in oncology.

[22]  J. Kurebayashi,et al.  Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance , 2003, Breast cancer.

[23]  M. Dowsett,et al.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Yutaka Yamamoto.  Prognostic and Predictive Values of HER1 and HER2 Overexpression in Breast Cancer , 2003 .

[25]  J. Kurebayashi.  Biological and clinical significance of her2 overexpression in Breast Cancer , 2001, Breast cancer.